# 🔄 ITERATIVE EXTRACTION PLAN
## Learning from `2025-11-19_09-12Z-designing-zero-tolerance-content-filtering-layer.md`

**File Size**: 31,629 lines  
**Approach**: Piece-by-piece systematic extraction  
**Goal**: Extract and learn EVERYTHING, not skip 99%

---

## 📋 EXTRACTION STRUCTURE

### **PHASE 1: FOUNDATION UNDERSTANDING** (Lines 1-5000)
**Goal**: Understand the initial context, questions, and early assessments

#### Piece 1.1: Initial SAE Assessment (Lines ~250-350)
- What agent understood about SAE initially
- What was unclear
- Confidence breakdown
- What needed verification

#### Piece 1.2: Manager Policy Discovery (Lines ~350-900)
- Manager feedback search process
- Policy documents found
- Manager's answers to SAE questions
- SAE lift gate policy
- Critical audit findings

#### Piece 1.3: SAE vs Evo2 Clarification (Lines ~1077-1125)
- Paper analysis
- What SAE actually is
- Current implementation vs real SAE
- What's needed for real SAE

#### Piece 1.4: Context Awareness Check-In (Lines ~1136-1400)
- What Zo was tracking
- Recent conversation flow
- Active files and documents
- Current mission context
- Strategic context
- Technical context
- Gaps and questions

---

### **PHASE 2: IMPLEMENTATION DISCOVERY** (Lines 5000-15000)
**Goal**: Understand what was built, how, and why

#### Piece 2.1: Phase 1 Implementation Complete (Lines ~5042-5200)
- What was built (Evo2 activations, SAE service, routers)
- Guardrails and safety measures
- Feature flags
- Provenance tracking

#### Piece 2.2: Manager Approval Process (Lines ~5107-5200)
- What manager needed to approve
- Manager's concrete answers
- Outcome selection (TCGA Ovarian platinum)
- Success criteria
- Resource allocation
- Build scope

#### Piece 2.3: Sprint Planning (Lines ~5910-6000)
- Sprint 1: SAE Phase 2 Core
- Sprint 2: Feature Interpretation
- Sprint 3: Zeta Oracle & Forge
- Sprint 4: Clinical Systems
- Sprint 5: Frontend Integration

#### Piece 2.4: Autonomous Work Status (Lines ~10220-10300)
- Sprint 1 completion
- Sprint 2 planning
- Deliverables
- Current blockers
- Next steps

#### Piece 2.5: Deployment Instructions (Lines ~10370-10800)
- Modal CLI & Auth
- Evo2 service deployment
- SAE service deployment
- Health checks
- Running cohort extraction

---

### **PHASE 3: TECHNICAL EXECUTION** (Lines 15000-25000)
**Goal**: Learn the technical details, bugs, fixes, and solutions

#### Piece 3.1: Mock Data Testing (Lines ~10000-10200)
- Mock cohort generation
- Pipeline verification
- Statistical correctness checks
- Performance metrics
- Verification criteria

#### Piece 3.2: Real Data Extraction (Lines ~11000-12000)
- Cohort file status
- pyBioPortal integration
- Variant mapping
- Extraction execution
- Data structure

#### Piece 3.3: Bug Discovery and Fixes (Lines ~20000-21000)
- Modal SAE errors
- Checkpoint loading issues
- ModuleList attribute errors
- Weight loading problems
- Fix implementations

#### Piece 3.4: Circuit Breaker and Error Handling (Lines ~31000-31300)
- Circuit breaker mechanism
- Error rate monitoring
- Failed patient handling
- Checkpoint resume logic
- Cost controls

---

### **PHASE 4: BIOMARKER ANALYSIS** (Lines 25000-31420)
**Goal**: Understand biomarker discovery process and results

#### Piece 4.1: Biomarker Correlation Service (Lines ~10000-10100)
- Service implementation
- Statistical methods
- Correlation analysis
- Effect size calculations
- Cross-validation

#### Piece 4.2: Pre-Flight Checklist (Lines ~30150-30200)
- Data verification
- Service readiness
- Script existence
- Output directory
- Class balance

#### Piece 4.3: Dataset Assessment (Lines ~30200-30300)
- Dataset strength
- Class imbalance
- Sample size considerations
- Recommendations

#### Piece 4.4: Feature Index Bug Fix (Lines ~30900-31000)
- Bug identification
- Root cause analysis
- Fix implementation
- Verification
- Re-extraction

---

### **PHASE 5: INTEGRATION & COMPLETION** (Lines 25000-31420)
**Goal**: Understand WIWFM integration design, clinical scenarios, and final implementation status

#### Piece 5.1: WIWFM Integration Architecture (Lines ~25040-25290)
- Integration architecture design
- Step 1: Extract Patient SAE Features
- Step 2: Drug-Specific Biomarker Mapping
- Step 3: Compute Drug-Specific SAE Score
- Step 4: Apply SAE Boost to WIWFM Confidence
- Integration into Drug Scorer
- Status: PENDING (awaiting validation)

#### Piece 5.2: Clinical Scenarios & Limitations (Lines ~25293-25520)
- Scenario 1: BRCA1 with Low DNA Repair (sensitive)
- Scenario 2: BRCA1 Reversion (resistant)
- Scenario 3: KRAS Hotspot (no correlation)
- Technical Limitations (5 limitations)
- RUO Guardrails (7 policies)

#### Piece 5.3: Implementation Inventory & Metrics (Lines ~25524-25683)
- Phase 1: SAE Service (COMPLETE)
- Phase 2: Cohort Extraction (COMPLETE)
- Phase 3: Biomarker Correlation (COMPLETE)
- Phase 4: WIWFM Integration (PENDING)
- Phase 5: Documentation (COMPLETE)
- Key Metrics from Logs
- Conclusion: From DNA to Decisions

#### Piece 5.4: Mutation Extraction Discovery (Lines ~12000-12200)
- Discovery: Labels file has no mutations
- Problem: Missing mutation data
- Solution: pyBioPortal extraction required
- Honest assessment of what was done vs not done

#### Piece 5.5: Modal Payload Size Fix (Lines ~28000-28100)
- Problem: 268M floats in JSON response
- Root cause: Full feature tensor serialization
- Fix: Return only top-k features
- Impact: Reduced payload from 1-2GB to ~1KB

---

## 🎯 EXTRACTION METHODOLOGY

### **For Each Piece:**

1. **Read** the section completely (no skipping)
2. **Extract** all key information:
   - Technical details
   - Decisions made
   - Rationale
   - Code changes
   - Bug fixes
   - Manager feedback
   - Strategic context
3. **Document** findings in structured format
4. **Cross-reference** with codebase when mentioned
5. **Build** understanding incrementally
6. **Verify** understanding before moving to next piece

### **Documentation Format:**

For each piece, create:
- **Summary**: What this section contains
- **Key Findings**: Important information extracted
- **Technical Details**: Code, configurations, implementations
- **Decisions**: Manager decisions, architectural choices
- **Bugs/Fixes**: Problems encountered and solutions
- **Context**: How this relates to other pieces
- **Questions**: Unanswered questions or gaps

---

## 📊 PROGRESS TRACKING

- [ ] Phase 1: Foundation Understanding
  - [ ] Piece 1.1: Initial SAE Assessment
  - [ ] Piece 1.2: Manager Policy Discovery
  - [ ] Piece 1.3: SAE vs Evo2 Clarification
  - [ ] Piece 1.4: Context Awareness Check-In

- [ ] Phase 2: Implementation Discovery
  - [ ] Piece 2.1: Phase 1 Implementation Complete
  - [ ] Piece 2.2: Manager Approval Process
  - [ ] Piece 2.3: Sprint Planning
  - [ ] Piece 2.4: Autonomous Work Status
  - [ ] Piece 2.5: Deployment Instructions

- [ ] Phase 3: Technical Execution
  - [ ] Piece 3.1: Mock Data Testing
  - [ ] Piece 3.2: Real Data Extraction
  - [ ] Piece 3.3: Bug Discovery and Fixes
  - [ ] Piece 3.4: Circuit Breaker and Error Handling

- [ ] Phase 4: Biomarker Analysis
  - [ ] Piece 4.1: Biomarker Correlation Service
  - [ ] Piece 4.2: Pre-Flight Checklist
  - [ ] Piece 4.3: Dataset Assessment
  - [ ] Piece 4.4: Feature Index Bug Fix

- [ ] Phase 5: Integration & Completion
  - [ ] Piece 5.1: WIWFM Integration Architecture
  - [ ] Piece 5.2: Clinical Scenarios & Limitations
  - [ ] Piece 5.3: Implementation Inventory & Metrics
  - [ ] Piece 5.4: Mutation Extraction Discovery
  - [ ] Piece 5.5: Modal Payload Size Fix

---

## 🚀 STARTING NOW

Beginning with **Piece 1.1: Initial SAE Assessment** (Lines ~250-350)

